Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

SAP-001 Promising for Refractory Gout

Michele B. Kaufman, PharmD, BCGP  |  May 9, 2025

Initial findings from a phase 2b clinical trial demonstrate the safety and efficacy of three different daily doses of SAP-001 to lower the serum urate levels of patients with refractory gout.

Filed under:ConditionsDrug UpdatesGout and Crystalline ArthritisResearch Rheum Tagged with:GoutGout Resource Centerrefractory goutSAP-001

Cilnidipine Receives Orphan Drug Status to Treat Systemic Sclerosis

Michele B. Kaufman, PharmD, BCGP  |  May 9, 2025

Based on research showing improved signs and symptoms of systemic sclerosis in patients taking cilnidipine vs. placebo, the FDA granted orphan drug designation for the agent.

Filed under:Biologics/DMARDsConditionsDrug UpdatesSystemic Sclerosis Tagged with:AISA-021cilnidipineFDASScsystemic sclerosis (SSc)U.S. Food and Drug Administration (FDA)

Nipocalimab Receives Breakthrough Therapy Status for Sjögren’s Disease

Michele B. Kaufman, PharmD, BCGP  |  May 9, 2025

Nipocalimab, an investigational monoclonal antibody that blocks FcRn and reduces levels of circulating immunoglobulin G (IgG) antibodies, has received the FDA’s breakthrough therapy designation for the treatment of Sjögren’s disease.

Filed under:Biologics/DMARDsConditionsDrug UpdatesSjögren’s Disease Tagged with:FDAnipocalimabSjogren'sU.S. Food and Drug Administration (FDA)

Editor's Pick

Incorporating Patient-Reported Outcomes into the Clinic

Katie Robinson  |  May 5, 2025

‘Measuring patient-reported outcomes (PROs) is an important component of high-quality, patient-centered care, but integration of PROs into clinic can be challenging,’ says Physician Editor Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS. ‘Luckily, tools exist to help us realize this vital aspect of patient care.’ The ACR’s quality measures for care include gauging disease activity and…

Filed under:EMRsPatient PerspectivePractice Support Tagged with:patient reported outcomes

FDA Approves Suzetrigine (VX-548), a Non-Opioid Analgesic

Michele B. Kaufman, PharmD, BCGP  |  April 29, 2025

Based on research in post-surgery patients, the FDA approved suzetrigine, a non-opioid analgesic, for the treatment moderate to severe, acute pain in adults.

Filed under:AnalgesicsDrug Updates Tagged with:acute painFDAFDA approvalsuzetrigineU.S. Food and Drug Administration (FDA)VX-548

Colin Edgerton, MD, Testifies in Congressional Hearing on Biosimilars

Vanessa Caceres  |  April 21, 2025

In front of the U.S. House Ways and Means Subcommittee, Dr. Edgerton described how challenges of biosimilar costs threaten patient care and outlined several potential legislative solutions.

Filed under:InsuranceLegislation & Advocacy Tagged with:BiosimilarsWays and Means Committee

FDA Approves Oral Solution of Colchicine to Prevent Gout Flare

Michele B. Kaufman, PharmD, BCGP  |  April 9, 2025

The FDA approved an oral solution of colchicine for the prevention of gout flare in adults. Its dosage can be easily adjusted on the basis of patient needs.

Filed under:AnalgesicsConditionsDrug UpdatesGout and Crystalline Arthritis

Doctor is using the tablet to send the data to the virtual reality glasses showing the health diagnosis as the patient is wearing and analyzing together at home.

Virtual Reality: An Immersive Educational Experience

Jason Liebowitz, MD, FACR  |  April 8, 2025

Virtual reality technology may be a unique and immersive avenue for educating patients on rheumatic conditions and their treatments, with the potential to enable more informed decision making and improve care.

Filed under:AppsEducation & TrainingTechnology Tagged with:appsEducationpatient educationTechnologyvirtual reality

Semaglutatide for Patients with Knee Osteoarthritis?

Bryn Nelson, PhD  |  April 8, 2025

Based on decades of data from dietary and other lifestyle interventions, doctors have long known that significant weight loss can be an effective treatment for people who are overweight and have knee osteoarthritis (OA). One meta-analysis showed that OA pain, function and stiffness scores improved by 2% for every 1% in lost weight.1 But the…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone DisordersResearch Rheum Tagged with:knee osteoarthritisResearch Reviewresearch reviewssemaglutideweight loss

Rheumatology Influencers: Dr. Huffstutter Leads with Purpose

Linda Childers  |  April 8, 2025

As president elect of the Tennessee Medical Association (TMA), J. Eugene Huffstutter, MD, FACP, FACR, MACR, a rheumatologist with Arthritis Associates in Hixson, Tenn., says one of his priorities as the new president of the Tennessee Medical Association (TMA) is ensuring physicians can focus on practicing medicine without unnecessary obstacles. Dr. Huffstutter expresses concern about…

Filed under:Profiles Tagged with:Access to careDr. Eugene Huffstutterprior authorizationRheumatology Influencers

  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 326
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences